Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04726241 · ClinicalTrials.gov registry record · Phase 1

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by PedAL BCU.

Recruiting
Registry status
Phase 1
Development phase
960
Enrollment target
20
Study locations

NCT04726241: Recruiting Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by PedAL BCU.

NCT04726241 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that is actively recruiting participants, run by PedAL BCU. The registered enrollment target is 960 participants, above the 113-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (750% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04726241, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, is actively recruiting participants, sponsored by PedAL BCU.

RECRUITING
Registry status
Phase 1
Development phase
960 participants
Enrollment target
20
Study locations

Study Summary

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Primary Outcome

The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confidence interval will be constructed.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia Juvenile Myelomonocytic Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy

Interventions

  • PROCEDURE Biospecimen Collection

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • Loma Linda University Medical Center - Loma Linda
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Rady Children's Hospital - San Diego - San Diego
  • UCSF Medical Center-Mission Bay - San Francisco

Arizona

  • Banner Children's at Desert - Mesa
  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Alabama

  • Children's Hospital of Alabama - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Colorado

  • Children's Hospital Colorado - Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver

Alaska

  • Providence Alaska Medical Center - Anchorage

Arkansas

  • Arkansas Children's Hospital - Little Rock

Trial Details

FieldValue
Enrollment Target 960 participants
Start Date 2022-04-18
Est. Completion 2030-12-31
Phase Phase 1
PedAL BCU

3 total trials

What NCT04726241 shows while recruiting

NCT04726241 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (750% higher).

The record links to 8 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.

NCT04726241 names 20 study sites across 6 states, led by California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04726241 about?

NCT04726241 is a clinical study titled "The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study". This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informati...

What is the current status of trial NCT04726241?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 960 participants. The study started on 2022-04-18. Estimated completion is 2030-12-31.

What conditions does trial NCT04726241 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia.

What interventions are being tested in trial NCT04726241?

The interventions under investigation include: Biospecimen Collection (PROCEDURE).

Who is sponsoring clinical trial NCT04726241?

This trial is sponsored by PedAL BCU, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04726241 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04726241's enrollment target sits among peer trials

960 6th of 306 higher than 301 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05142384 · 960 participants · NA

    ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start

  • NCT05178498 · 960 participants

    Impact of Dietary Inflammatory Potential on Breast Cancer Risk

  • NCT05946629 · 960 participants · NA

    SELUTION 4 De Novo Small Vessel IDE Trial

  • NCT06764485 · 960 participants · Phase 3

    A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04726241

Source: ClinicalTrials.gov NCT04726241, the US trial registry maintained by the National Library of Medicine. NCT04726241 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.